BENDAMUSTINE HYDROCHLORIDE AND RITUXIMAB WITH OR WITHOUT BORTEZOMIB FOLLOWED BY RITUXIMAB WITH OR WITHOUT LENALIDOMIDE IN TREATING PATIENTS WITH HIGH-RISK STAGE II, STAGE III, OR STAGE IV FOLLICULAR LYMPHOMA: